Making cervical cancer prevention accessible at scale.
Qvintip® is a clinically validated, single-use self-sampling device designed for scalable, public health screening, including low-resource settings.
The Problem
Cervical cancer is preventable, yet too many women are still dying.
HPV infections can be detected long before cancer develops, but screening programs fail to reach enough women. Clinic-based models create barriers that leave populations unscreened or under-screened.
Late detection is not a failure of medicine.
It is a failure of reach.
The Solution
Aprovix expands access to cervical cancer screening with self-sampling Qvintip®.
A clinically validated at-home, easy-to-use, self-test for HPV detection with the same accuracy as sampling performed at a clinic. Designed for scale, it integrates seamlessly into screening programs.
Preventing cervical cancer is not about new science.
It is about making proven screening reach more women.
A clinically proven self-sampling solution for HPV screening
Key Benefits
Increased participation in screening programs
Clinical accuracy comparable to clinician-collected samples
Reduced burden on healthcare infrastructure
Cost-efficient implementation at population level
Evidence & Validation
20+ years of clinical research
100,000+ women in clinical studies
Validated with leading HPV assays
ISO 13485 certified
Aligned with WHO HPV screening guidance
Designed for public health, laboratories and global partners
Public screening programs
Diagnostic laboratories
NGOs & global health initatives
Commercial distributors
Aligned with the World Health Organization’s Cervical Cancer Elimination Initiative